All News
Addressing CV Risk in RA: Are we doing enough?
ORAL surveillance was a post-authorisation safety study of tofacitinib 5mg and 10mg versus TNF inhibitors, focusing on rates of adverse events, including MACE. A higher incidence of MACE was observed with the use of tofacitinib. Statins are recommended in patients with a history of atherosclerotic disease or 10 year predicted risk of MACE. But, how many patients with rheumatoid arthritis, at risk of MACE, are actually taking a statin?
Read Article![](https://pbs.twimg.com/media/GcqdTEDbgAAwv0U.jpg)
![](https://pbs.twimg.com/media/GcqbhnJbUAAyUmH.jpg)
![](https://pbs.twimg.com/media/GcqNj1faQAEir3d.png)
![](https://pbs.twimg.com/media/GcqX9dNaEAA9kY4.png)
![](https://pbs.twimg.com/media/GcpcRmIa8AAq72G.png)
Always looking for cancer/CV signals from JAKi in big observational datasets w extensive JAKi use nationwide 🇯🇵 claims data RA pts n=52k (JAKi n=4.3k) Cancer with JAKi vs TNFi: aHR 2.2 (esp lung, lymphoma) This is a problem. Watch these data. #ACR24 ABST1336 @RheumNow #ACRBest https://t.co/vsnT46De6T
![](https://pbs.twimg.com/media/GcqRzjsa0AAgtv9.png)
![](https://pbs.twimg.com/media/GcqO6aZaoAAwM9I.jpg)
Links:
![](https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg)
Richard Conway RichardPAConway ( View Tweet)
![](https://pbs.twimg.com/media/GcpAF_GawAAzYHn.jpg)
![](https://pbs.twimg.com/media/GcqT4ILaQAAqFWH.png)
![](https://pbs.twimg.com/media/GcphHbUbUAAoThN.png)
![](https://pbs.twimg.com/media/Gcqk_UuboAAs2RX.png)
Links:
![](https://pbs.twimg.com/media/GcpFaKNb0AMpjb6.png)
![](https://pbs.twimg.com/media/GcqoJcDaAAAOTiv.png)
![](https://pbs.twimg.com/media/GcpWKnNasAA3Jn4.png)
![](https://pbs.twimg.com/media/GcqpoQmakAAxWFx.png)
![](https://pbs.twimg.com/media/GcqrmuTa8AA4h-4.jpg)
![](https://pbs.twimg.com/media/GcpYECKbEAAR6Cw.jpg)
![](https://pbs.twimg.com/media/GcqstosbAAEDzrx.png)